Entrada Therapeutics, Inc. (TRDA) return on invested capital (ROIC)

Return on invested capital · fiscal 2025
-203.3%

Entrada Therapeutics, Inc. (TRDA) earned a return on invested capital of -203.3% in fiscal 2025 (the year ended December 31, 2025). That is 271.6 percentage points lower than the 68.4% of fiscal 2024. Figures as of 17 Nov 2026, 23:49 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on invested capital, fiscal 2025
-203.3%
Change on fiscal 2024
−271.6 pts
Highest on record
68.4%fiscal 2024
Lowest on record
-203.3%fiscal 2025
Fiscal years on record
32022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Entrada Therapeutics, Inc. return on invested capital (ROIC), in more detail

Across the 3 fiscal years on record (2022–2025), the highest was 68.4% in fiscal 2024 and the lowest -203.3% in fiscal 2025.

History · 3 fiscal years

Return on invested capital by fiscal year

Entrada Therapeutics, Inc. return on invested capital (ROIC), year by year

Entrada Therapeutics, Inc. (TRDA) return on invested capital (ROIC) by fiscal year
Fiscal yearReturn on invested capitalChangeYear ended
2025-203.3% 271.6 pts down
202468.4%—
2022-154.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

How to read it

It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.

More on TRDA

Entrada Therapeutics, Inc., figure by figure

Entrada Therapeutics, Inc. (TRDA) overview: price, valuation and scorecard

Entrada Therapeutics, Inc. return on invested capital (ROIC): questions and answers

What is Entrada Therapeutics, Inc.'s return on invested capital?

Entrada Therapeutics, Inc. (TRDA) earned a return on invested capital of -203.3% in fiscal 2025 (the year ended December 31, 2025). That is 271.6 percentage points lower than the 68.4% of fiscal 2024.

What are the highest and lowest return on invested capital figures on record for Entrada Therapeutics, Inc.?

Across the 3 fiscal years on record (2022–2025), the highest was 68.4% in fiscal 2024 and the lowest -203.3% in fiscal 2025.

How is Entrada Therapeutics, Inc.'s return on invested capital calculated?

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Entrada Therapeutics, Inc. (TRDA) return on invested capital (ROIC)”, data as of 17 November 2026. https://funkfolio.com/stock/TRDA/roic

Underlying data: the company's filings with the SEC and Yahoo Finance.